Introduction:
Eli Lilly invests US$9 million in the newest Indiana site to boost API production for tirzepatide and pipeline medicines in USA.
Features:
This expansion will increase the capacity to manufacture active pharmaceutical ingredients (API) for Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection, allowing more adults with chronic conditions such as obesity and type 2 diabetes to benefit from these vital treatments.
The multi-site campus will produce cutting-edge medications, including Zepbound and Mounjaro, support pipeline growth, and utilise the latest technology and automation for optimal efficiency, safety, and quality control.
Significantly, this investment creates high-wage, advanced manufacturing, engineering, and science jobs.
As part of this additional investment, the Lebanon site expects to add 200 full-time jobs for highly skilled workers, including engineers, scientists, operating personnel, and lab technicians, resulting in an estimated 900 full-time employees when the facility is fully operational.
The site is anticipated to start manufacturing medicines in Lebanon toward the end of 2026, with operations scaling up through 2028.
Specifications:
Name Eli Lilly
Type New Construction
Budget US$9 billion
Year 2028
